Quote | Fsd Pharma Inc. Subordinate Voting Shares (CNQC:HUGE:CC)
Last: | $1.26 |
---|---|
Change Percent: | -2.33% |
Open: | $1.29 |
Close: | $1.26 |
High: | $1.29 |
Low: | $1.24 |
Volume: | 162,587 |
Last Trade Date Time: | 05/06/2022 04:57:08 pm |
News | Fsd Pharma Inc. Subordinate Voting Shares (CNQC:HUGE:CC)
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, announced that the U.S. District Court for the Eastern District of Pennsylvania has confir...
TORONTO, ON / ACCESSWIRE / May 31, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that on May 29,...
Message Board Posts | Fsd Pharma Inc. Subordinate Voting Shares (CNQC:HUGE:CC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Fsd Pharma Inc. Subordinate Voting Shares Company Name:
HUGE:CC Stock Symbol:
CNQC Market:
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, announced that the U.S. District Court for the Eastern District of Pennsylvania has confir...
TORONTO, ON / ACCESSWIRE / May 31, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that on May 29,...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a clinical trial protocol to assess the safety and efficacy of Unbuzzd(TM) i...